The First and Only Medical Technology Designed for Both In-Clinic and At-Home Therapy of Resistant Depression
Disclaimer: Neurolief’s technology for the treatment of Major Depressive Disorder is considered investigational and therefore not yet granted marketing authorization.
Disclaimer: Neurolief’s technology for the treatment of Major Depressive Disorder is considered investigational and therefore not yet granted marketing authorization.
Major depressive disorder (MDD) is a global epidemic, impacting millions and inflicting severe emotional and physical suffering. Despite its widespread prevalence, effective and accessible treatment options remain limited, especially for those with treatment-resistant depression (TRD) who fail to respond to conventional therapies. The situation is worsened by a significant shortage of psychiatrists, further increasing the barriers to access for those seeking care.
No effective home treatment exists for TRD, underscoring the urgent need for innovative solutions. By addressing this unmet need we can transform mental healthcare, improve countless lives, and disrupt this stagnant market to significantly reduce the global burden of depression.
of disability worldwide¹
of US adults experience major depression²
people die by suicide each year worldwide¹
of patients are resistant to traditional therapies¹
the estimated annual economic burden of MDD in the US alone³
1 World health organization. Depression 2021
2 NIH – National Institute of Mental Health. Major Depression 2022
3 Greenberg PE et al. The Economic Burden of Adults with Major Depressive Disorder in the United States. Pharmacoeconomics. 2021 Jun;39 (6):653-665.
Neurolief’s groundbreaking therapy treats major depression by stimulating the release of neurotransmitters in the brainstem and modulating mood-related brain networks.
Our state-of-the-art medical technology utilizes three adaptive channels to non-invasively deliver precise electrical pulses through major neural pathways in the head, reaching the brainstem and higher brain regions implicated in depression. Designed for both in-clinic and at-home use, the system includes a wearable neuromodulation unit, a patient-friendly mobile app and a cloud-based data tracking and analytics. This advanced setup enables physicians to follow-up patients, analyze data and tailor treatments, thereby enhancing therapy outcomes.
Neurolief’s pioneering approach marks a major leap forward in the treatment of depression. By combining cutting-edge technology with personalized home-based care, we’re transforming the future of mental health and profoundly impacting the lives of those affected by depression.
Our advanced platform expands physicians’ capabilities by bringing care directly into each patient’s home, significantly advancing depression management and extending the clinician’s ability to handle the growing number of these patients.
The MOOD pivotal clinical study marks a historic landmark as the first ever Randomized Controlled Trial (RCT) to demonstrate success in a non-pharmacological home therapy for treatment-resistant depression.
For the first time, participants in the study achieved substantial improvement through a home-based therapy.
of patients showed
substantial clinical
improvement*
of patients
achieved full remission**
Unanticipated serious
adverse events
Neurolief Inc.
10211 W. Sample Rd. #217
Coral Springs, FL 33065
1-888-4RELIVION (888-473-5484)
Disclaimer: Neurolief’s technology for the treatment of Major Depressive Disorder is considered investigational and therefore not yet granted marketing authorization.